Shopping Cart
Remove All
Your shopping cart is currently empty
Irosustat (667-Coumate) is a potent steroid sulfatase inhibitor, with an IC50 of 8 nM, and exhibits anti-breast cancer activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | In Stock | In Stock | |
| 5 mg | $47 | In Stock | In Stock | |
| 10 mg | $80 | In Stock | In Stock | |
| 25 mg | $173 | In Stock | In Stock | |
| 50 mg | $292 | In Stock | In Stock | |
| 100 mg | $417 | In Stock | In Stock | |
| 200 mg | $593 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $48 | In Stock | In Stock |
| Description | Irosustat (667-Coumate) is a potent steroid sulfatase inhibitor, with an IC50 of 8 nM, and exhibits anti-breast cancer activity. |
| Targets&IC50 | Steroid sulfatase:IC50:8 nM, Steroid sulfatase (MCF-7 cells):0.2 nM |
| In vitro | Irosustat (667 COUMATE), a potent steroid sulfatase inhibitor, exhibits an IC50 of 8 nM and inhibits steroid sulfatase (STS) activity in MCF-7 cells with an IC50 of 0.2 nM, without affecting the morphology or proliferation of MCF-7 cells at 10 μM. |
| In vivo | Irosustat effectively inhibits over 90% of rat liver activity at a concentration of 1 mg/kg. At doses of 2 mg/kg administered orally for five days, it impedes uterine growth induced by oestrone sulfate (E1S) in ovariectomized rats. Additionally, when combined with E1S, Irosustat, at dosages of 2 and 10 mg/kg administered orally, reduces the growth of NMU-induced mammary tumors in these rats in a dose-dependent manner. Moreover, at a dosage of 10 mg/kg administered orally, Irosustat (identified as 667 COUMATE) achieves a 97.9 ± 0.06% inhibition of steroid sulphatase (STS) activity in rat liver. |
| Cell Research | MCF-7 cells are cultured in growth medium (minimum essential medium (MEM) containing, phenol red, 10% foetal calf serum (FCS) and essential nutrients). When the cells reach 60% confluency, they are treated with Irosustat (0.001-10 μM) in growth medium. After 72 h of incubation, photographs are taken under normal conditions of light and the number of attached cells in each flask is determined using a Coulter cell counter |
| Animal Research | Irosustat is formulated in propylene glycol.RatsLudwig rats bearing mammary tumors are used in the assay. Tumor development is monitored, and animals are ovariectomized when tumors reach 0.8-1.5 cm in diameter. Tumors are allowed to regress over a 12- to 13-day period to confirm their hormone-dependent status. Regrowth of tumors is stimulated with oestrone sulfate (E1S; 50 μg/day, s.c.). When tumors have regrown, animals continue to receive either E1S alone or E1S plus Irosustat at 10 mg/kg/day or 2 mg/kg/day, p.o., until tumor regression has occurred. Tumor volumes are calculated from two measured diameters. |
| Synonyms | STX64, BN83495, 667-Coumate |
| Molecular Weight | 309.34 |
| Formula | C14H15NO5S |
| Cas No. | 288628-05-7 |
| Smiles | NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1 |
| Relative Density. | 1.48 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (177.8 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.47 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.